Dilution is a way of life in the biotech industry. The timeline for getting drugs through each phase of development and in front of the FDA for approval takes many years. More often than not, a few handfuls of them. That kind of timeline requires boatloads of cash, and one of the most common ways to get it is by selling additional shares of stock. Today, Brenton Flynn and Max Macaluso outline some of the most recent offerings to hit the market, including one company with a massive 150% increase in shares outstanding since the end of 2011.
Brenton Flynn, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
